**Supplementary Table 2: Summary of centrally assessed RCB**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Arm A** | | | **Arm B** | | |
|  | **All**  **n = 61**  **n (%)** | **HR+**  **n = 49**  **n (%)** | **TNBC**  **n = 12**  **n (%)** | **All**  **n = 62**  **n (%)** | **HR+**  **n = 48**  **n (%)** | **TNBC**  **n = 14**  **n (%)** |
| **RCB 0** | 5 (8.2%) | 5 (10.2%) | 0 (0%) | 4 (6.5%) | 1 (2.1%) | 3 (21.4%) |
| **RCB 1** | 3 (4.9%) | 3 (6.1%) | 0 (0%) | 3 (4.8%) | 3 (6.3%) | 0 (0%) |
| **RCB 2** | 34 (55.7%) | 25 (51.1%) | 9 (75%) | 31 (50%) | 25 (52%) | 6 (42.9%) |
| **RCB 3** | 17 (27.9%) | 15 (30.6%) | 2 (16.7%) | 23 (37.1%) | 18 (37.5%) | 5 (35.7%) |
| **Missing** | 2 (3.3%) | 1 (2%) | 1 (8.3%) | 1 (1.6%) | 1 (2.1%) | 0 (0%) |

Abbreviations: HR+, hormone receptor positive; RCB, residual cancer burden; TNBC, triple negative breast cancer.